Articles By Cyndi Root

  1. Hodgkin Lymphoma Patients Show High Response To Bristol-Myers Squibb's Opdivo 12/10/2014

    Bristol-Myers Squibb (BMS) reported positive results from a Phase 1b trial evaluating Opdivo (nivolumab) in patients with relapsed or refractory hematological malignancies.

  2. Gilead Shows Long-Term Safety, Disease Control In Zydelig For Lymphomas 12/10/2014

    Gilead Sciences reports that Zydelig (idelalisib) offers long-term benefits for lymphoma patients.

  3. Johnson Matthey Acquires Scottish Manufacturing Facility From Bakhu Pharma 12/9/2014

    Johnson Matthey, a British multinational company, has acquired a manufacturing facility in Scotland, where it intends to produce active ingredients and provide custom pharmaceutical services.

  4. Zosano, Eli Lilly Partner On Parathyroid Hormone Patch For Osteoporosis 12/5/2014

    Zosano Pharma and Eli Lilly have partnered to develop Zosano's parathyroid hormone 1-34 (PTH).

  5. Otsuka Acquires Avanir For Neurologic Disease Pipeline 12/5/2014

    Otsuka Pharmaceutical has agreed to acquire Avanir Pharmaceuticals. The companies announced the deal in a press release, stating that Otsuka will pay approximately $3.5 billion for Avanir shares in cash.

  6. Mylan To Manufacture, Distribute Gilead's TAF Treatment For HIV In 112 Countries 12/5/2014

    Mylan and its subsidiary Mylan Laboratories have entered into an agreement with Gilead Sciences regarding the manufacturing and distribution of Tenofovir Alafenamide (TAF) for the treatment of HIV-1 infection.

  7. Weekly FDA Enforcement Report For Drugs 11/26/14 12/4/2014

    The Food and Drug Administration (FDA) has released its Drug product Enforcement Report for November 26, 2014. The agency publicizes recalls in its weekly report as press releases are not issued for all recalls. Manufacturers issue recalls voluntarily or the FDA initiates the action. View the recalls by Classification.

  8. Flamel Sells French Manufacturing Facility To Recipharm 12/4/2014

    Flamel Technologies has agreed to sell its manufacturing facility in France to Recipharm, a contract development and manufacturing organization (CDMO). The companies announced the sale in a press release, stating the deal relieves Flamel from the duties of running a manufacturing facility.

  9. Eisai Opens New Manufacturing Facility In The U.K., Expands Presence In China 12/4/2014

    Eisai has completed the construction of its U.K. manufacturing facility and held opening ceremonies on November 26, 2014. The company announced the opening in a press release, stating that the new packaging facility is in Hatfield, Hertfordshire. Eisai Manufacturing, a subsidiary of Eisai, operates the facility.

  10. Daiichi Sankyo, UCB Partner To Market Lacosamide For Epilepsy In Japan 12/4/2014

    Daiichi Sankyo and UCB Biopharma have formed a partnership to market Lacosamide (brand name Vimpat), an epilepsy treatment, in Japan. The companies announced the deal in a press release, stating that UCB will manufacture and supply the product.